



NDA 019949/S-070
NDA 019950/S-069
NDA 020090/S-051

SUPPLEMENT APPROVAL

Pfizer Inc.
Attention: Michele Burtness
Senior Manager, Pfizer Global Regulatory Affairs
235 East 42nd Street
New York, NY 10017-5755

Dear Ms. Burtness:

Please refer to your supplemental new drug applications (sNDAs) dated and received March 2, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA 019949/S-070 Diflucan (fluconazole tablets)
NDA 019950/S-069 Diflucan (fluconazole in dextrose injection and fluconazole in sodium chloride injection, for intravenous use)
NDA 020090/S-051 Diflucan (fluconazole for oral suspension)

These Prior Approval supplemental new drug applications provide for revisions to the prescribing information (PI) as follows:

- (1) *Terfenadine* and *Cisapride* have been removed from the **CLINICAL PHARMACOLOGY** section, **Drug Interaction Studies** subsection;
- (2) Coadministration of *terfenadine*, *cisapride* and *astemizole* have been removed from the **CONTRAINDICATIONS** section;
- (3) *Lemborexant* has been added and *Astemizole*, *Cisapride*, *Halofantrine*, and *Terfenadine* have been removed from the **PRECAUTIONS** section, **Drug Interactions** subsection,

Additionally, consequential updates have been made to **PATIENT INFORMATION**, for the tablet dosage form, as well as minor editorial revisions made throughout labeling.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling(s).

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and the Patient Package Insert) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labels.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 019949/S-070
NDA 019950/S-069
NDA 020090/S-051
Page 3

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - o Prescribing Information
 - o Patient Package Insert

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
10/25/2021 03:12:44 PM